Abstract
You have accessJournal of UrologyCME1 May 2022MP42-15 UROTHELIAL CARCINOMA OF THE BLADDER WITH ISOLATED LYMPH NODE METASTASIS: NATURAL HISTORY AND OUTCOMES FOLLOWING SURGICAL RESECTION Ernest Morton, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Simon Kim, Joaquim Bellmunt, Irving Kaplan, Aria Olumi, and Boris Gershman Ernest MortonErnest Morton More articles by this author , Sumedh KaulSumedh Kaul More articles by this author , Aaron FleishmanAaron Fleishman More articles by this author , Ruslan KoretsRuslan Korets More articles by this author , Peter ChangPeter Chang More articles by this author , Andrew WagnerAndrew Wagner More articles by this author , Simon KimSimon Kim More articles by this author , Joaquim BellmuntJoaquim Bellmunt More articles by this author , Irving KaplanIrving Kaplan More articles by this author , Aria OlumiAria Olumi More articles by this author , and Boris GershmanBoris Gershman More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002608.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Pathologic lymph node involvement (cN0 pN+) carries a poor prognosis in patients with urothelial carcinoma of the bladder (UCB), and there are limited contemporary data describing the natural history of UCB in such patients following radical cystectomy (RC) with pelvic lymph node dissection (PLND). We therefore utilized a nationwide oncology dataset to examine the natural history and outcomes of cN0 pN+ UCB after RC and PLND. METHODS: We identified patients in the National Cancer Database (NCDB) with cN0 pN+ cM0 UCB from 2006-2015 treated with RC and PLND. The associations of baseline characteristics with all-cause mortality (ACM) were evaluated using Cox regression. RESULTS: The study cohort consisted of 2,884 patients, including 42% with pN1 and 58% with pN2-3 disease. Of these, 606 (21%) received multiagent neoadjuvant chemotherapy, while 1,172 (41%) received post-operative adjuvant chemotherapy. A median of 15 (IQR 9-23) LNs were removed during PLND. The 5- and 8-year overall survival (OS) for the entire cohort were 20% and 17%, respectively (Fig. 1). Compared to the overall cohort, patients surviving >5 years had lower pN stage (59% vs 42% pN1) and pT stage (41% vs 22% ≤pT2). On multivariable analysis, higher pT stage (HR 2.84, 95% CI 1.15-5.33 for pT3, HR 3.33, 95% CI 1.76-6.29 for pT4 vs pT0) and pN stage (HR 1.27, 95% CI 1.14-1.42 for pN2-3 vs pN1) were associated with worse ACM, while greater number of LNs removed (HR 0.99, 95% CI 0.98-0.99) and receipt of adjuvant chemotherapy (HR 0.62, 95% CI 0.56-0.69) were associated with improved ACM (Table 1). CONCLUSIONS: While OS for cN0 pN+ M0 UCB is poor, a subset of patients demonstrates durable long-term survival with 5- and 8-year OS of 20% and 17%, respectively. Higher pT and pN stage represent adverse prognostic characteristics, while greater extent of PLND and administration of adjuvant chemotherapy represent potential interventions associated with improved OS. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e737 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ernest Morton More articles by this author Sumedh Kaul More articles by this author Aaron Fleishman More articles by this author Ruslan Korets More articles by this author Peter Chang More articles by this author Andrew Wagner More articles by this author Simon Kim More articles by this author Joaquim Bellmunt More articles by this author Irving Kaplan More articles by this author Aria Olumi More articles by this author Boris Gershman More articles by this author Expand All Advertisement PDF DownloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.